1. Alzheimer’s disease: the amyloid cascade hypothesis;Hardy;Science,1992
2. Alzheimer Precision Medicine Initiative (APMI). Precision pharmacology for Alzheimer’s disease;Hampel;Pharmacol. Res,2018
3. Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019;Knopman;Alzheimers Dement.,2021
4. EMA/CHMP/708314/2020, Committee for Medicinal Products for Human Use (CHMP) Minutes for the Meeting on 09–12 November 2020, 5 January 2021.
5. EMA/480969/2015, Stakeholders and Communication Division EMA regulatory tools for early access to medicines. Conditional Marketing Authorisation and Accelerated Assessment Draft Revised Guidelines – Description of Tools and Overview of Changes, 24 July 2015.